Mela Sciences Inc. (MELA US) jumped 11 percent, the most since Oct. 4, to $5.16. After receiving FDA approval for its tool for detecting the skin cancer melanoma, the New York-based company may rise as high as $20 over the next year, Barron’s reported, citing Needham & Co. analyst Dalton Chandler.
For more from BostonGlobe.com, sign up or log in below
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.